Clinical Trial Update: mXELOXIRI Combined With Molecular Targeted Drug in mCRC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mXELOXIRI plus a molecular targeted drug in unresectable metastatic colorectal cancer; status not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• mXELOXIRI

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Unresectable Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN